Acute administration of a single dose of valsartan improves left ventricular functions: A pilot study to assess the role of tissue velocity echocardiography in patients with systemic arterial hypertension in the TVE-valsartan study I

Clinical Physiology and Functional Imaging

Volumn 26, Issue 6, 2006, Pages 351-356

  Govind, Satish C ^a   Brodin, Lars Åke ^b   Nowak, Jacek ^a,b   Ramesh, S S ^a   Saha, Samir K ^b  

^a BMJ Heart Center   (India)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Hypertension; Myocardial function; Strain rate imaging; Tissue velocity echocardiography; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART AFTERLOAD; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYSTOLE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PILOT PROJECTS; RESEARCH DESIGN; STROKE VOLUME; SWEDEN; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE; VENTRICULAR FUNCTION, LEFT;

EID: 33750127257     PISSN: 14750961     EISSN: 1475097X     Source Type: Journal    
DOI: 10.1111/j.1475-097X.2006.00704.x     Document Type: Article

References (23)

1. Baicu CF, Zile MR, Aurigemma GP, Gaasch WH. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation (2005); 111: 2306-2312.
2. Cain PA, Ahl R, Hedstrom E, Ugander M, Allansdotter-Johnsson A, Friberg P, Marild S, Arheden H. Physiological determinants of the variation in left ventricular hypertrophy from early adolescence to late adulthood in healthy subjects. Clin Physiol Funct Imaging (2005); 25: 1-8.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The jnc 7 report. JAMA (2003); 289: 2560-2572.
4. Cohn JN, Tognoni G, Valsartan for the Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med (2001); 345: 1667-1675.
5. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet (2002); 359: 995-1003.
6. Donal E, Thibault H, Bergerot C, Loufouat J, Ovize M, Derumeaux GA. Validation of 2D strain: A comparison with sonomicrometry and conventional strain imaging (Abstr). Eur Heart J (2005); 26 (Abstract Supplement): 105.
7. Fraser AG, Payne N, Madler CF, Janerot-Sjoberg B, Lind B, Grocott-Mason RM, Ionescu AA, Florescu N, Wilkenshoff U, Lancellotti P, Wutte M, Brodin LA, MYDISE Investigators. Feasibility and reproducibility of off-line tissue Doppler measurement of regional myocardial function during dobutamine stress echocardiography. Eur J Echocardiogr (2003); 4: 43-53.
8. Gottdiener JS, Livengood SV, Meyer PS, Chase GA. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. J Am Coll Cardiol (1995); 25: 424-430.
9. Govind SC, Roumina S, Brodin LÅ, Nowak J, Ramesh SS, Saha SK. Differing myocardial response to a single session of hemodialysis in end-stage renal disease with and without type 2 diabetes mellitus and coronary artery disease. Cardiovasc Ultrasound (2006); 4: 9 (February 2, 2006).
10. Jugdutt BI, Menon V. Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction. J Card Fail (2004); 10: 74-82.
11. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet (2004); 363: 2022-2031.
12. Levi BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system (Review). Circulation (2004); 109: 8-13.
13. Lind B, Nowak J, Cain P, Quintana M, Brodin LA. Left ventricular isovolumic velocity and duration variables calculated from colour-coded myocardial velocity images in normal individuals. Eur J Echocardiogr (2004); 5: 284-293.
14. Marwick TH. Measurement of strain and strain rate by echocardiography: ready for prime time ? J Am Coll Cardiol (2006); 47: 1313-1327.
15. de Mello WC, Crespo MJ. Correlation between changes in morphology, electrical properties, and angiotensin-converting enzyme activity in the failing heart. Eur J Pharmacol (1999); 378: 187-194.
16. Messerli FH, Mehra MR. Crumbling of left ventricular hypertrophy as a surrogate end point [the losartan for intervention for endpoint reduction in hypertension (life) study editorial]. Am J Cardiol (2002); 90: 1133-1134.
17. Palka P, Lange A, Fleming AD, Donnelly JE, Dutka DP, Starkey IR, Shaw TR, Sutherland GR, Fox KA. Differences in myocardial velocity gradient measured throughout the cardiac cycle in patients with hypertrophic cardiomyopathy, athletes and patients with left ventricular hypertrophy due to hypertension. J Am Coll Cardiol (1997); 30: 760-768.
18. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003); 349: 1893-1906.
19. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Diez J. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation (2000); 101: 1729-1735.
20. Saha SK, Brodin LA, Lind B, Svedenhag J, Straat E, Gunnes S. Myocardial velocities measured during adenosine, dobutamine and supine bicycle exercise: A tissue Doppler study in healthy volunteers. Clin Physiol Funct Imaging (2004); 24: 281-288.
21. Wachtell K, Smith G, Gerdts E, Dahlof B, Nieminen MS, Papademetriou V, Bella JN, Ibsen H, Rokkedal J, Devereux RB. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Am J Cardiol (2000); 85: 466-472.
22. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet (2004); 363: 2049-2051.
23. Weidemann F, Jamal F, Sutherland GR, Claus P, Kowalski M, Hatle L, Scheerder ID, Bijnens B, Rademakers FE. Myocardial function defined by strain rate and strain during alterations in inotropic states and heart rate. Am J Physiol Heart Circ Physiol (2002); 283: H792-H799.